Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

ARD podcast

المحتوى المقدم من BMJ Group. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرةً بواسطة BMJ Group أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

2+ y ago 20:37

MP3•منزل الحلقة

سلسلة مؤرشفة ("تلقيمة معطلة" status)

When? This feed was archived on January 11, 2024 13:13 (3M ago). Last successful fetch was on November 28, 2022 08:56 (1+ y ago)

Why? تلقيمة معطلة status. لم تتمكن خوادمنا من جلب تلقيمة بودكاست صحيحة لفترة طويلة.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies. Christophe Richez, Department of Rheumatology, University Medical Center, Bordeaux, France, and ARD's Social Media Advisor, interviews Bimba Hoyer, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Germany, and Rebecca H Haberman, Division of Rheumatology, University Grossman School of Medicine, New York, USA. They describe their works and offer their thoughts on the current situation in this area and the future. Related content: https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220272

https://ard.bmj.com/content/early/2021/06/07/annrheumdis-2021-220597

25 حلقات

#Health and Well-Being #Medicine #Science #Rheumatic Diseases #BMJ Group